CA-ARCULES
11.2.2020 17:32:06 CET | Business Wire | Press release
Arcules , leading innovators in integrated video and access control cloud services, today announced the commercial availability of the Arcules-XProtect Hybrid™ VMS Solution in North America and Europe. The solution represents a combination of the Arcules Video Surveillance as a Service (VSaaS) integrated with Milestone XProtect Corporate on-premise video management software (VMS). The result is a flexible and feature-rich hybrid video surveillance solution ideal for organizations looking to centralize their dispersed video surveillance operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005274/en/
With Arcules-XProtect Hybrid VMS Solution, Milestone XProtect customers can deploy remote sites quickly, with minimal IT resources and downtime while still benefiting from the strong capabilities of XProtect on-premise VMS. Additionally, Arcules’ intuitive platform provides sites and cameras connected to Arcules VSaaS an underlying cloud infrastructure such as compatibility between sites, low video latency, data encryption, redundancy, streamlined maintenance with automatic updates, and easy onboarding.
“Milestone resellers and end customers are planning their deployment to take advantage of the many benefits of cloud computing. This integration gives Milestone XProtect Corporate customers a new hybrid cloud computing deployment option,” said Bjørn Skou Eilertsen, CTO of Milestone Systems. “The typical Milestone XProtect Corporate user has many branch offices of different sizes and locations. Enabling this hybrid deployment option can allow them to simplify large scale deployments. After the Arcules system is Interconnected the user can utilize these Arcules connected cameras with the advanced XProtect Corporate product capabilities.”
The Arcules-XProtect Hybrid VMS Solution uses Milestone Interconnect™ technology to combine the hyper-scalability and licensing flexibility of Arcules cloud service with the feature-rich video management functions of XProtect Corporate. The combination of these advanced technologies provides uniform access to live video, recordings and alarms across cameras physically connected on-premise and virtually connected via the Arcules cloud, through XProtect Smart Client, XProtect Smart Wall, and the web and mobile clients.
Organizations with distributed locations such as healthcare, retail, corporate campuses and education, and utility environments all benefit from high-performance cloud services to provide real-time insight in the event of an incident in remote areas. The Arcules-XProtect Hybrid VMS Solution also adds value to monitoring stations and law enforcement organizations that use XProtect Corporate as their VMS platform. Such organizations can now access cameras and customers subscribed to the Arcules cloud service directly from their on-premise XProtect system.
“The Arcules-XProtect Hybrid VMS Solution is an ideal solution for businesses looking to expand their surveillance operation across geographically dispersed locations,” said Arcules CEO Andreas Pettersson. “These businesses can enjoy the strong capabilities of on-premise VMS while reducing their capital investment. The solution also enables organizations to better manage their operational costs as a result of flexible pricing schemes and minimal hardware requirements.”
The Arcules-XProtect Hybrid VMS Solution regional availability outside of North America and Europe is based on market demand conditioned by datacenter availability and/or the possibility to utilize data centers in other regions.
Arcules will demonstrate the solution in booth #809 at the MIPS 2020 Conference , February 17-19, at the Gaylord Texan in Grapevine, TX as well as in Arcules booth #31081 and Milestone booth #18053 during the 2020 ISC West Conference and Expo , March 17-20, at the Sands Expo in Las Vegas.
About Arcules
Arcules, a Canon Group company, addresses the unmet need of modern enterprises for integrated cloud-based video surveillance, access control and analytics. Using the latest developments in cloud, artificial intelligence and machine learning, Arcules combines previously untapped video monitoring data with sensor data and analytics to deliver actionable insights that ultimately drive better business decisions, optimize operations and improve safety. Arcules is headquartered in Irvine, Calif. Visit www.arcules.com for more information and follow us on LinkedIn , Facebook , and Twitter .
About Milestone Systems
Milestone Systems is a leading provider of open platform video management software; technology that helps the world see how to ensure safety, protect assets and increase business efficiency. Milestone enables an open platform community that drives collaboration and innovation in the development and use of network video technology, with reliable and scalable solutions that are proven in more than 500,000 installations worldwide. Founded in 1998, Milestone is a stand-alone company in the Canon Group. For more information visit: http://www.milestonesys.com . For news and other press releases, visit our Newsroom . Click here for information on Trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005274/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom